Skip to main content
TipRanks
Go Ultimate75% OFF

Gilead Sciences (GILD) Revenue by Type

14,051 Followers

Revenue by Type

Gilead Sciences reported revenue by type of $8.30B in Q3 2026, up 6.4% from Q2 2026 and up 6.8% year over year. This is the highest value since 2019.

Analyzes income from different sources, highlighting which areas are driving growth and which might be underperforming, crucial for assessing the company's financial health and strategic focus.

$0.00$2.00B$4.00B$6.00B$8.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Product sales are the clear growth engine — steady, upward momentum driven by HIV/PrEP strength and oncology launches that prompted management to raise product/base guidance. ‘Other’ is highly erratic and driven by one‑off items (nonrecurring other revenue, licensing/transactional effects), producing outsized spikes that can misleadingly swing reported results. For investors, prioritize the underlying product trajectory and HIV/PrEP/Trodelvy momentum rather than headline EPS volatility from acquisition accounting and tax distortions; watch cell‑therapy softness and lower COVID sales as potential near‑term offsets to product gains.

GILD Revenue by Type

PeriodOtherProductTotal
Q3 2026Sep 30, 2026$11.00M$8.29B$8.30B
Q2 2026Jun 30, 2026$176.00M$7.63B$7.80B
Q1 2026Mar 31, 2026$14.00M$6.95B$6.96B
Q4 2025Dec 31, 2025$22.00M$7.90B$7.92B
Q3 2025Sep 30, 2025$424.00M$7.34B$7.77B
Q2 2025Jun 30, 2025$27.00M$7.05B$7.08B
Q1 2025Mar 31, 2025$54.00M$6.61B$6.67B
Q4 2024Dec 31, 2024$33.00M$7.54B$7.57B
Q3 2024Sep 30, 2024$30.00M$7.51B$7.54B
Q2 2024Jun 30, 2024$41.00M$6.91B$6.95B
Q1 2024Mar 31, 2024$39.00M$6.65B$6.69B
Q4 2023Dec 31, 2023$45.00M$7.07B$7.12B
Q3 2023Sep 30, 2023$56.00M$6.99B$7.05B
Q2 2023Jun 30, 2023$35.00M$6.56B$6.60B
Q1 2023Mar 31, 2023$46.00M$6.31B$6.35B
Q4 2022Dec 31, 2022$56.00M$7.33B$7.39B
Q3 2022Sep 30, 2022$64.00M$6.98B$7.04B
Q2 2022Jun 30, 2022$122.00M$6.14B$6.26B
Q1 2022Mar 31, 2022$56.00M$6.53B$6.59B
Q4 2021Dec 31, 2021$84.00M$7.16B$7.24B
Q3 2021Sep 30, 2021$65.00M$7.36B$7.42B
Q2 2021Jun 30, 2021$65.00M$6.15B$6.22B
Q1 2021Mar 31, 2021$83.00M$6.34B$6.42B
Q4 2020Dec 31, 2020$93.00M$7.33B$7.42B
Q3 2020Sep 30, 2020$84.00M$6.49B$6.58B
Q2 2020Jun 30, 2020$76.00M$5.07B$5.14B
Q1 2020Mar 31, 2020$81.00M$5.47B$5.55B
Q4 2019Dec 31, 2019$83.00M$5.80B$5.88B

Related KPIs